Haemonetics to Present at Bank of America 2026 Healthcare Conference
Rhea-AI Summary
Haemonetics (NYSE: HAE) announced that President and CEO Chris Simon will speak in a fireside chat at the Bank of America 2026 Healthcare Conference on May 12, 2026 at 8:00 a.m. PT.
According to the company, a live webcast will be available on Haemonetics' Investor Relations website and a replay will be posted within 24 hours and hosted for one year.
Positive
- None.
Negative
- None.
News Market Reaction – HAE
In the May 5 session, HAE gained 0.54%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 24 | Clinical study data | Positive | +0.5% | Study showed strong safety and efficacy for VASCADE MVP XL in large-bore access. |
| Apr 01 | Earnings timing update | Positive | +1.1% | Set date and access details for Q4 and FY 2026 earnings release. |
| Mar 30 | FDA labeling approval | Positive | +2.6% | FDA approved expanded VASCADE MVP XL labeling for larger procedural sheaths. |
| Feb 23 | Regulatory clearance | Positive | +0.6% | FDA 510(k) clearance for NexSys PCS with Persona PLUS after large pivotal trial. |
| Feb 20 | Conference appearance | Positive | +0.2% | CEO fireside chat at Raymond James investor conference with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially regulatory wins and conference appearances, has typically led to modest positive price reactions, suggesting orderly alignment between news tone and stock moves.
Over the past months, Haemonetics has reported several regulatory and clinical milestones alongside routine investor events. In Feb 2026, it gained FDA 510(k) clearance for NexSys PCS with Persona PLUS and later secured FDA approval for expanded VASCADE MVP XL labeling, both followed by small positive moves. Conference and scheduling updates in Feb and Apr 2026 also saw slight gains. Against this backdrop, today’s Bank of America conference appearance fits a pattern of ongoing investor engagement rather than a new fundamental catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/75d0U1.cfm.
A replay of the recorded webcast will become accessible within 24 hours after the event and will be available for one year on Haemonetics' Investor Relations website.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Sr. Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-to-present-at-bank-of-america-2026-healthcare-conference-302762054.html
SOURCE Haemonetics Corporation